Nothing compares to the hands-on lab experience, say the high school students, many of whom decide to continue their studies as undergraduates at The University of Arizona.
Author Archive: AZBio
HTG Molecular Diagnostics Announces Second Companion Diagnostic Development Project with QIAGEN
HTG is Developing NGS Gene Expression Profiling Assays for Multiple Cancer TherapiesContinue reading
Living computers: RNA circuits transform cells into nanodevices
ASU Biodesign researcher shows how cells can be induced to carry out computations — with implications in health and energy.Continue reading
Paradigm Announces Major Price Reduction in Flagship Paradigm Cancer Diagnostic (PCDx)
On July 24, 2017, Paradigm Diagnostics announced a major price reduction of PCDx. “The efficiency of our proprietary process and transition to an optimized platform enables us to share the savings with our patients, customers, research partners, and distributors without impacting our industry leading accuracy, speed, and comprehensiveness,” said David Mallery, CEO.
Study identifies new brain death pathway in Alzheimer’s disease
Findings of team led by ASU scientists offer hope for therapies targeting cell loss in the brain, an inevitable and devastating outcome of Alzheimer’s progression.Continue reading
Partnering with U.S. Army to improve Ebola detection
To catch a serial killer, homicide detectives must quickly and accurately find clues. Trace evidence left at a crime scene will eventually reveal the killer’s presence and identity, but the detectives first have to know what to look for.Continue reading
BRAIN center gathers to ponder future, direction
For all its resiliency and creativity, the human brain is equally fragile and prone to disease. Millions around the world are affected by neurological and neurodegenerative diseases. In fact, a World Health Organization study found eight out of 10 disorders in the three highest disability classes are linked to neurological problems, a figure likely to increase, as the global elderly population is expected to double by 2050.Continue reading
Insys Therapeutics, Inc. appoints Andrew G. Long as Chief Financial Officer
PHOENIX, July 18, 2017 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) announced today that Andrew G. Long has joined the company as Chief Financial Officer, effective August 7, 2017.